← All Immix Biopharma, INC filings

Immix Biopharma, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
IMMX
Immix Biopharma, INC
10-K/A: Immix Biopharma Amends 2025 Annual Report, Boosts Cash
Immix Biopharma, Inc. filed an amendment to its 2025 Annual Report on Form 10-K, primarily to correct the auditor report date, while revealing significant capital raises and increased liquidity despite growing net losses.
NASDAQ
IMMX
Immix Biopharma, INC
10-K: Immix Biopharma's NXC-201 Shows Strong Phase 2 Data, Secures Funding
Immix Biopharma reports positive interim Phase 2 data for its lead CAR-T candidate NXC-201 in AL Amyloidosis, alongside significant capital raises and key regulatory designations.
NASDAQ
IMMX
Immix Biopharma, INC
10-K/A: Immix Biopharma Files Amended 10-K to Include XBRL Tagging, Reaffirms Financial Officer Certifications
Immix Biopharma files an amendment to its 2024 annual report to include required XBRL tagging and reaffirms certifications from its principal executive and financial officers.
NASDAQ
IMMX
Immix Biopharma, INC
10-K: Immix Biopharma Reports 2024 10-K Filing, Highlights NXC-201 Clinical Data and RMAT Designation
Immix Biopharma's 2024 10-K filing details financial results, NXC-201 clinical trial progress, and recent RMAT designation for relapsed/refractory AL amyloidosis.
NASDAQ
IMMX
Immix Biopharma, INC
10-K: Immix Biopharma Reports Full Year 2023 Results, Highlights Clinical Progress
Immix Biopharma's 2023 annual report details ongoing clinical trials, financial losses, and strategic developments in their pursuit of novel cancer and autoimmune therapies.